Controlled release

nanexa

for better healthcare

Q3

Interim report
July – September 2026

Nanexa AB (PUBL)

Significant events during the third quarter of 2026

- Nanexa announced on September 24 a global license and collaboration agreement with Novo for long-acting injectables. The agreement is valued at EUR 1.165 billion, including an upfront payment of EUR 20 million, followed by EUR 595 million in development and regulatory milestone payments. The remaining milestone payments are sales related. In addition, Nanexa is entitled to a low single-digit royalty on global net sales of products developed under the agreement. The agreement grants Novo a global exclusive license to Nanexa's proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in obesity, type 2 diabetes and other cardiometabolic diseases.
- Nanexa announced on September 22 a joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines with Forge Nano. The collaboration intends to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa's broad portfolio of proprietary and partnered PharmaShell® programs.

Financial overview

1 July - 30 September 2026

- Turnover amounted to: TSEK 227,865 (477)
- Operating profit (EBIT) amounted to: TSEK 157,332 (-11,983)
- Profit after tax amounted to: TSEK 157,384 (-12,538)
- Earnings per share before dilution amounted to: SEK 0.82 (-0.08) SEK
- Earnings per share after dilution amounted to: SEK 0.80 (-0.07) SEK
- Cash flow for the period amounted to: TSEK -8,524 (-15,483)
- Cash and cash equivalents at end of period: TSEK 44,033 (24,779)

1 January - 30 September 2026

- Turnover amounted to: TSEK 231,151 (6,059)
- Operating profit (EBIT) amounted to: TSEK 129,840 (-25,433)
- Profit after tax amounted to: TSEK 129,329 (-27,424)
- Earnings per share before dilution amounted to: SEK 0.70 (-0.18) SEK
- Earnings per share after dilution amounted to: SEK 0.68 (-0.15) SEK
- Cash flow for the period amounted to: TSEK -534 (14,488)
- Cash and cash equivalents at end of period: TSEK 44,033 (24,779)

Figures in brackets refer to the corresponding period in the previous year.

CEO’s comment



The third quarter of 2026 has been one of the most strategically important periods in Nanexa's development, primarily through the agreement with Novo, but also through significant scientific and operational progress.

Most notably, we announced a global licence and collaboration agreement with Novo on September 24. Under the agreement, Novo has a global exclusive license to develop up to five peptide drugs using PharmaShell® for indications including obesity, type 2 diabetes and other cardiometabolic diseases. The programs cover different administration-frequency profiles, with monthly and quarterly administration as target profiles. This is something we have already demonstrated in initial studies that we can achieve with our PharmaShell® platform.

This landmark collaboration could result in payments to Nanexa of up to EUR 1.165 billion, of which EUR 595 million relates to development and regulatory milestone payments, and represents important external validation of the strength and commercial potential of our PharmaShell® platform. I am very pleased with the upfront payment of EUR 20 million, that as we see is well in line with market practice.

The payment is a very welcome addition to our cash position and, in my view, fundamentally changes our financial position. I am also very pleased with the balance and timing of the milestone payments included in the agreement, which provides a basis for a further strengthening of our cash position in the coming years. The agreement also provides for sales-based milestone payments of EUR 550 million, as well as a low single-digit royalty on future product sales, creating the potential for recurring revenues for Nanexa well into the 2030s.

As our chairman Göran Ando has remarked, the collaboration represents a new era of considerable financial strength for Nanexa and will allow us to significantly accelerate development activities while expanding application of PharmaShell® to other therapeutic areas. It also transforms Nanexa into a truly sustainable, long-term business, allowing us to progress projects further along their development before partnering, which could help to generate further deals that are extremely financially attractive.

The deal was widely reported in Sweden and abroad in leading international media such as The Wall Street Journal and Bloomberg.

The collaboration with Moderna is also on track and making strong progress. We are excited to be working with one of the world's leading biotechnology companies in the rapidly expanding field of mRNA therapeutics, and the collaboration allows us to explore the potential of PharmaShell® in this highly innovative area of medicine.

Meanwhile, internal development of different PharmaShell® formulations has continued, with the associated in vivo studies. These studies are generating important data that supports our strategy of developing an internal pipeline of drug candidates in different disease areas based on the PharmaShell® platform.

In addition, I'm pleased to report that we have taken an important step towards future commercial-scale manufacturing through the initiation of our collaboration with Forge Nano, a U.S. company specializing in manufacturing solutions for ALD technology.

As interest in PharmaShell® grows and development programs advance, establishing a clear path towards large-scale manufacturing is a key strategic priority. This collaboration represents an important building block that will prepare Nanexa for future commercial opportunities.

Looking back on the quarter, I am immensely proud of what the Nanexa team has accomplished. The Novo agreement is the result of years of focused work, scientific innovation and perseverance. It reflects the dedication of our employees and the strength of the technology platform we have built together. While this achievement marks a major milestone, we believe it is only the beginning. With a strong financial position, a growing portfolio of strategic collaborations and continued momentum across our programs, we are entering the next phase of Nanexa's development with confidence and excitement.

David Westberg, CEO

Financial comments

Result and cash flow

Third quarter 2026

Sales for the quarter amounted to SEK 227,865 (477) thousand, of which SEK 226,420 (0) thousand relates to the new license agreement with Novo, SEK (0) 477 thousand to other feasibility studies regarding the PharmaShell® technology and SEK 1,445 (0) thousand to the coating of sensors. During the period, development costs amounting to SEK 4,369 (4,157) thousand were capitalized, relating both to investments in the PharmaShell® technology and to final investments in the NEX-22 projects.

External project and development costs amounted to SEK -51,891 (-3,024) thousand during the quarter. This includes the impairment of the full carrying amount of the NEX-22 projects as a result of the agreement with Novo, as, from an accounting perspective, this means that Nanexa has disposed of the projects to which Novo now holds exclusive rights. The closing balance of intangible assets represents the projects in which Nanexa retains an economic interest.

Other external costs, including costs for premises and external consultants, amounted to SEK -13,803 (-5,658) thousand. The increase was largely attributable to consultancy fees, travel expenses and legal advice in connection with the agreement with Novo. Personnel costs for the quarter amounted to SEK -5,904 (-4,812) thousand, with the increase mainly attributable to the company having more employees than in the corresponding period of the previous year.

The result for the quarter amounted to SEK 157,384 (-12,538) thousand.

Cash flow for the quarter amounted to SEK -8,524 (-15,483) thousand. The change in working capital amounted to SEK -225,929 (-53) thousand and mainly comes from a temporary significant increase of accounts receivables.

Cash flow from investing activities amounted to SEK -6,885 (-5,629) thousand. Investments in intangible fixed assets amounted to -6,576 (-5,629) thousand. The investment in tangible fixed assets was SEK -390 (0) thousand.

The cash flow from financing activities amounted to SEK 15,332 (-422) thousand, where new share issues contributed with SEK 15,606 (1,542) thousand. Transaction costs amounted to SEK -189 (-1,587) thousand and amortization of loans amounted to SEK -85 (-377) thousand.

The period January – September 2026

Sales for the period amounted to SEK 231,151 (6,059) thousand, of which SEK 226,420 (0) thousand relates to the new exclusivity agreement with Novo, SEK 2,081 (540) thousand to other feasibility studies regarding the PharmaShell® technology, SEK 0 (4,303) thousand to the previous exclusivity agreement with Novo and SEK 2,650 (1,208) thousand to the coating of sensors. During the period, development costs amounting to SEK 13,308 (15,061) thousand were capitalized, relating both to investments in the PharmaShell® technology and to final investments in the NEX-22 projects.

External project and development costs during the period amounted to SEK -58,917 (-10,775) thousand. This includes the impairment of the full carrying amount of the NEX-22 projects as a result of the agreement with Novo, as, from an accounting perspective, this means that Nanexa has disposed of the projects to which Novo now holds exclusive rights. The closing balance of intangible assets represents the projects in which Nanexa retains an economic interest.

Other external costs, including costs for premises and external consultants, amounted to SEK -27,095 (-18,569) thousand. The increase was largely attributable to consultancy fees, travel expenses and legal advice in connection with the agreement with Novo. Personnel costs in the period amounted to SEK -18,560 (-15,092) thousand, where the increase mainly comes from a higher headcount.

The result for the period amounted to SEK 129,329 (-27,424) thousand.

Cash flow for the period amounted to SEK -534 (-14,488) thousand. The change in working capital amounted to SEK -219,239 (-1,030) thousand and mainly comes from a temporary significant increase of accounts receivables.

Cash flow from investing activities amounted to SEK -22,865 (-19,027) thousand. Investments in intangible fixed assets amounted to -17,991 (-19,027) thousand. The investments in tangible fixed assets amounted to SEK -4,874 (0) thousand.

The cash flow from financing activities amounted to SEK 54,098 (52,769) thousand, where new share issues contributed with SEK 79,626 (38,537) thousand. Transaction costs amounted to SEK -4,817 (-4,701) thousand and amortization/change of loans amounted to SEK -20,712 (-1,067) thousand.

Financial position

As of 30 September 2026, cash and cash equivalents and short-term investments amounted to SEK 44,033 (27,779) thousand and equity amounted to SEK 305,669 (77,337) thousand.

Employees

The number of employees as of 30 September 2026, was 17 (15), of which 4 (4) women and 13 (11) men. The average number of employees (FTE) amounted to 17 (15) in the third quarter of 2026 and 15 (14) during January-September. In addition to employed staff, Nanexa continuously retains consultants with specialist expertise.

Related party transactions

During January-September 2026, Nanexa had the following related party transactions. The company had identified a temporary need for the expertise possessed by the chairman of the board, Göran Ando. This need concerned tasks including, but not limited to, business development and strategy work, where the nature and extent had been deemed to go beyond what is normally required of a board chairman. Against this background, the company and Göran Ando had entered into an agreement under which Göran Ando was employed part-time on market terms from 1 January to 30 September 2026. The remuneration amounted to SEK 120,000 per month.

The share

Nanexa AB (publ) was listed on the Nasdaq First North Growth Market on 29 May 2020. The share was previously listed on the Spotlight Stock Market since 17 June 2015. As of 30 September 2026, the number of shareholders in Nanexa was 12,766.

Earnings per share

Earnings per share before and after dilution amounted to SEK 0.82 (-0.08) for the third quarter of 2026. For the period of January-September 2026, earnings per share amounted to 0.70 (-0.18) before dilution and 0.68 (-0.15) after dilution.

Number of shares

The number of outstanding shares in Nanexa AB as of 30 September 2026 was 194,938,097 (158,676,146), with a quota value of SEK 0.13 per share. The number of shares at full dilution of outstanding warrants was 197,286,535 (178,232,089). The average number of shares for the third quarter amounted to 191,250,411 (158,609,084). Including full dilution of outstanding warrants, the average number of shares for the third quarter amounted to 197,286,535 (184,786,535). The average number of shares for January-September amounted to 184,047,848 (154,811,865). Including full dilution of outstanding warrants, the average number of shares for the period amounted to 190,258,147 (178,232,089).

The outstanding programs for warrants by 30 September 2026 were:

TO9 (2026/2027) that can be used to subscribe for shares between 25 May 2026 and 30 June 2027. Each warrant in the series entitles the holder to subscribe for one (1) share. If the entire T09 (2026/2027) program was to be exercised, the resulting dilution would amount to 3.27%. As of 30 September 2026, the number of outstanding Series TO9 warrants amounted to 2,348,438, of which 1,350,000 warrants were subscribed for before 30 September 2026, but paid for and registered after. The subscription price is SEK 4.00.

Accounting principles for preparing the report

The interim report has been prepared in accordance with the same accounting principles as in the company's most recent annual report, i.e., in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general recommendations BFNAR 2012:1 Annual Report and Consolidated Accounts (K3).

Upcoming reporting

Nanexa AB plans to provide the following financial reports:

12 February 2027	Year-end report 2026
1 April 2027	Annual report 2026
29 April 2027	Interim report January – March 2027
26 August 2027	Interim report April-June 2027
4 November 2027	Interim report July-September 2027

The company's financial year is 1 January - 31 December.

This interim report has not been subject to a comprehensive audit by the company's auditors.

Uppsala 04/11/2026

The board of directors, Nanexa AB

Göran Ando (chairman)

David Westberg, CEO Nanexa AB | Richard Davis (member) | Jakob Dynnes Hansen (member)

Birgit Stattin Norinder (member) | Hanna Tilus (member)

Income statement

Amounts in TSEK	01/07/2026 – 30/09/2026	01/07/2025 – 30/09/2025	01/01/2026 – 30/09/2026	01/01/2025 – 30/09/2025	01/01/2025 – 31/12/2025
Operating revenue					
Turnover	227,865	477	231,151	6,059	36,149
Capitalised development costs	4,369	4,157	13,308	15,061	19,787
Other income	102	88	187	7,443	7,499
Total revenue	**232,336**	**4,722**	**244,645**	**28,563**	**63,435**
Operating expenses					
External project and development costs	-51,891	-3,024	-58,917	-10,775	-13,644
Other external expenses	-13,803	-5,658	-27,095	-18,569	-24,838
Personnel costs	-5,904	-4,812	-18,560	-15,092	-20,376
Depreciation on intangible and tangible fixed assets	-3,435	-3,175	-10,038	-9,296	-12,538
Other operating costs	30	-37	-195	-264	-807
Total costs	**-75,004**	**-16,705**	**-114,805**	**-53,996**	**-72,203**
Operating profit (EBIT)	**157,332**	**-11,983**	**129,840**	**-25,433**	**-8,768**
Profit/loss from financial items					
Interest income and similar income statement items	116	100	413	349	389
Interest expenses and similar income statement items	-92	-682	-1,005	-2,421	-3,117
Total profit/loss from financial items	**24**	**-582**	**-592**	**-2,072**	**-2,728**
Taxes					
Tax revenue	27	27	81	81	108
Total taxes	**27**	**27**	**81**	**81**	**108**
Profit/loss for the period	**157,384**	**-12,538**	**129,329**	**-27,424**	**-11,388**
Earnings per share before dilution (SEK)	**0.82**	**-0.08**	**0.70**	**-0.18**	**-0.07**
Earnings per share after dilution (SEK)	**0.80**	**-0.07**	**0.68**	**-0.15**	**-0.06**

Balance Sheet

Amounts in TSEK	30/09/2026	30/09/2025	31/12/2025
Assets			
Fixed assets			
Intangible fixed assets	36,054	71,159	74,306
Tangible fixed assets	12,750	10,553	9,837
Financial fixed assets	505	397	424
Total fixed assets	**49,310**	**82,108**	**84,567**
Current assets			
Stock	0	144	128
Current receivables	233,314	7,026	8,879
Short-term deposits	0	15,000	36,398
Cash and cash equivalents	44,033	9,779	8,169
Total current assets	**277,347**	**31,950**	**53,575**
Total assets	**326,657**	**114,058**	**138,142**
Equity and liabilities			
Equity			
Share capital	25,229	20,536	20,575
Unregistered share capital	175	0	492
Restricted equity	24,391	61,471	64,498
Share premium reserve	426,922	348,822	356,450
Profit and loss account reserve brought forward	-328,431	-326,069	-329,095
Profit/loss for the period	157,384	-27,424	-11,388
Total equity	**305,669**	**77,337**	**101,531**
Non-current liabilities			
Liabilities to credit institutions	710	21,374	1,116
Total non-current liabilities	**710**	**21,374**	**1,116**
Current liabilities			
Accounts payable	6,091	3,061	2,884
Other current liabilities	14,187	12,286	32,611
Total current liabilities	**20,278**	**15,347**	**35,495**
Total equity and liabilities	**326,657**	**114,058**	**138,142**
Pledged assets	**7,015**	**7,015**	**7,015**
Assets with retention of title	**5,043**	**6,363**	**6,033**

Cash flow analysis

Amounts in TSEK	01/07/2026 – 30/09/2026	01/07/2025 – 30/09/2025	01/01/2026 – 30/09/2026	01/01/2025 – 30/09/2025	01/01/2025 – 31/12/2025
Current activities					
Operating result	157,332	-11,983	129,840	-25,433	-8,768
Adjustments for items not included in cash flow	51,601	3,175	58,204	9,296	12,682
Interest received	82	110	414	333	385
Interest paid	-58	-682	-987	-2,421	-2,517
Cash flow from operating activities before change in working capital	**208,958**	**-9,380**	**187,471**	**-18,224**	**1,782**
Cash flow from change in working capital					
Change in inventories and work in progress	0	426	128	351	367
Changes in accounts receivable - trade	-225,553	-1,141	-224,529	977	-1,293
Change in receivables	355	106	146	788	438
Change in accounts payable - trade	-4,780	-27	3,207	772	595
Change in other liabilities	4,048	584	1,808	-3,918	-3,351
Total from change in working capital	**-225,929**	**-53**	**-219,239**	**-1,030**	**-3,244**
Cash flow from current activities	**-16,972**	**-9,432**	**-31,767**	**-19,254**	**-1,462**
Investing activities					
Investments in intangible fixed assets	-6,576	-5,629	-17,991	-19,027	-24,748
Investments in tangible fixed assets	-309	0	-4,874	0	0
Investments in financial fixed assets	0	0	0	0	0
Cash flow from investment activities	**-6,885**	**-5,629**	**-22,865**	**-19,027**	**-24,748**
Financing activities					
New share issue	15,606	1,542	79,626	38,537	46,738
Issue costs	-189	-1,587	-4,817	-4,701	-4,744
Borrowings	0	0	0	20,000	20,000
Amortisation of loans	-85	-377	-20,712	-1,067	-1,508
Cash flow from financing activities	**15,332**	**-422**	**54,098**	**52,769**	**60,486**
Cash-flow for the period	**-8,524**	**-15,483**	**-534**	**14,488**	**34,276**
Cash and cash equivalents at the beginning of the period	52,557	40,263	44,567	10,292	10,292
Cash and cash equivalents at the end of the period	**44,033**	**24,779**	**44,033**	**24,779**	**44,567**

Change in equity

Amounts in TSEK	Share capital	Not registered share capital	Fund for development work	Share premium reserve	Profit/Loss brought forward	Profit/Loss for the period	Total equity
Amount as of 01/01/2026	**20,575**	**492**	**64,498**	**356,450**	**-329,095**	**-11,388**	**101,531**
Previous year's result					-11,388	11,388	**0**
New share issue	808			19,191			**19,999**
Ongoing new issue		175					**175**
Subscription warrants	3,846	-492		56,098			**59,452**
Issue expenses				-4,816			**-4,816**
Capitalized development costs for the period			13,307		-13,307		**0**
Capitalized development change for the period			-48,165		48,165		**0**
Depreciation on capitalised development costs for the period			-5,250		5,250		**0**
Profit/loss for the period						129,329	**129,329**
Amount as of 30/09/2026	**25,229**	**175**	**24,391**	**426,922**	**-300,376**	**129,329**	**305,669**

Amounts in TSEK	Share capital	Not registered share capital	Fund for development work	Share premium reserve	Profit/Loss brought forward	Profit/Loss for the period	Total Equity
Amount as of 01/01/2025	**17,562**	**0**	**51,318**	**317,961**	**-291,011**	**-24,905**	**70,925**
Previous year's result					-24,905	24,905	**0**
New share issue	2,745			32,255			**35,000**
Ongoing new issue							**0**
Subscription warrants	229			3,308			**3,537**
Issue expenses				-4,701			**-4,701**
Capitalized development costs for the period			15,061		-15,061		**0**
Depreciation on capitalised development costs for the period			-4,907		4,907		**0**
Profit/loss for the period						-14,886	**-14,886**
Amount as of 31/12/2025	**20,536**	**0**	**61,471**	**348,822**	**-326,069**	**-27,424**	**77,337**

Pledged assets

Amounts in TSEK	30/09/2026	30/09/2025	31/12/2025
Corporate mortgages	7,015	7,015	7,015

Assets with retention of title

Amounts in TSEK	30/09/2026	30/09/2025	31/12/2025
Assets with retention of title	5,043	6,393	6,033

About Nanexa

Nanexa develops long-acting injectable medicines using PharmaShell®

Nanexa is a pharmaceutical company developing long-acting injectable medicines using its proprietary and patented drug delivery platform, PharmaShell®. The platform is based on Atomic Layer Deposition (ALD), where particles of active pharmaceutical ingredient are coated with an ultrathin inorganic layer. By adjusting the thickness and composition of the coating, the release profile can be controlled and the dosing interval extended from daily or weekly treatment to monthly, quarterly or longer.

Nanexa creates value through two complementary parts of its business: proprietary drug development programs, the NEX programs, and PharmaShell®-based programs conducted in collaboration with other pharmaceutical companies. The license agreements with Novo and Moderna, together with the development collaboration with Forge Nano, demonstrate the platform's commercial and industrial relevance.

Two paths to create value

In its proprietary NEX programs, Nanexa selects projects based on medical need, market potential and technical feasibility. Programs may be advanced to a value-creating milestone, such as clinical proof of concept, after which further development and commercialization may be pursued independently or together with a partner. In partner programs, Nanexa's formulation technology and manufacturing expertise are combined with the partner companies' compounds, development resources and commercial capabilities. Revenue may, for example, comprise upfront payments, milestone payments and royalties on future sales.

In September 2026, Nanexa entered into a global exclusive license and collaboration agreement with Novo for the use of PharmaShell® in up to five programs involving certain therapeutic peptide medicines, targeting monthly and quarterly administration profiles. The agreement may provide Nanexa with payments of up to EUR 1.165 billion, as well as a low single-digit royalty on global net sales.

In December 2025, Nanexa entered into a global license and option agreement with Moderna covering an initial compound and options for up to four additional compounds. The agreement includes an upfront payment of USD 3 million, up to USD 500 million in potential milestone payments, and tiered single-digit royalties.

Clinically validated platform and proprietary development program

PharmaShell® has been evaluated in preclinical and clinical studies. Phase I studies in NEX-18, NEX-20 and NEX-22 have demonstrated extended release of both small-molecule compounds and peptides. The platform has also been evaluated with proteins, monoclonal antibodies, oligonucleotides and mRNA, among other modalities, in internal studies and partner projects.

Nanexa's main focus is to support its collaboration partners in developing PharmaShell®-based products and the capabilities required to advance the programs. The collaboration with Novo concerns long-acting injectable formulations of certain therapeutic peptide medicines in areas including obesity, type 2 diabetes and other cardiometabolic diseases, targeting monthly and quarterly administration profiles. The collaboration with Moderna aims to evaluate the potential of PharmaShell® technology to improve the release profile of selected compounds. Together with Forge Nano, Nanexa is developing large-scale, GMP-compatible ALD manufacturing equipment to support clinical development and potential future commercial-scale production for proprietary and partner-led PharmaShell® programs.

A patented drug delivery system

In ALD, extremely thin layers of inorganic oxides are deposited one layer at a time onto each drug particle. Following injection, the particles form a depot. As the coating gradually dissolves, the drug particles are exposed, and the active substance is released. The release rate is controlled by the coating's composition and thickness, which can be tailored to achieve a desired depot duration ranging from weeks to several months.

PharmaShell® – key features

- **Controlled release:** The depot duration and initial release can be tailored through the design of the coating.
- **High drug load and low injection volume:** The coating constitutes a small proportion of the particle, and formulations typically contain approximately 80 per cent active pharmaceutical ingredient.
- **Unmodified active pharmaceutical ingredient:** PharmaShell® does not require chemical modification of the active substance.
- **Broad applicability:** The platform has been evaluated for small molecules and several biological modalities, including peptides, proteins, monoclonal antibodies, oligonucleotides and mRNA.
- **Protection and manufacturing advantages:** The coating protects the active substance within the depot and, for suitable products, may enable terminal sterilization and improved temperature stability.

Benefits of long-acting injectable medicines

For patients
Fewer administrations can reduce the treatment burden and facilitate adherence. Depending on the medicine, a low injection volume and more consistent exposure may contribute to a more patient-friendly treatment.

For healthcare systems
Longer dosing intervals can reduce the need for frequent administration and healthcare visits, while creating better conditions for treatment planning and follow-up.

For payers
Fewer administrations and healthcare contacts may reduce costs in certain treatments. The overall health-economic value depends on factors including the indication, treatment setting and clinical effect.

For pharmaceutical companies
The platform may enable differentiated long-acting product profiles and lifecycle development of validated medicines and may also be used for new drug substances.

Manufacturing and scale-up

Since 2020, Nanexa has operated its own GMP-certified facility in Uppsala for the manufacture of clinical trial material. The facility has produced PharmaShell® material for three Phase I studies. In September 2026, Nanexa and Forge Nano entered into a development agreement for large-scale, GMP-compatible ALD equipment, with the aim of supporting clinical development and potential future commercial production for proprietary and partner-led programs.

Sustainability and patent protection

Longer dosing intervals may, in certain treatments, reduce the number of injections, healthcare-related journeys and administration components. For products that can be stored at room temperature, the need for refrigerated transport and storage may also be reduced. The outcome depends on the individual product, manufacturing process and treatment setting.

PharmaShell® and key enabling technologies are protected by a growing patent portfolio. As of September 2026, the portfolio comprised 14 patent families with granted patents and patent applications in, or covering, up to 50 countries, with standard patent terms extending to 2046.

Contact

David Westberg
CEO
+46-709 42 83 03
david.westberg@nanexa.se

Nanexa AB

Virdings Allé 2, SE-754 50 Uppsala, Sverige
Phone: +46 (0) 18 100 300
Org nr. 556833-0285
info@nanexa.se